All Articles

Bispecific Agents (BsAGs) in Solid Tumors: Nurse Resource Guide

We are excited to share with you Bispecific Agents in Solid Tumors: Nurse Resource Guide, developed by nurse experts particularly for nursing and other medical professions. This guide will serve as a valuable resource for effectively implementing the use of bispecific agents for solid tumors in healthcare practice, including guidance on monitoring and managing adverse events.

Updates to NCCN Guidelines for Multiple Myeloma: Recently Approved First-Line Treatments for Patients With NDMM Eligible and Ineligible for Transplant

Evolving Landscapes in Multiple Myeloma, NCCN Guidelines, Highlights From NCCN, Multiple Myeloma

Web Exclusives

Two quadruplet therapies have been approved by the FDA as first-line treatment for patients with newly diagnosed multiple myeloma (NDMM) and updated in the NCCN guidelines for the treatment of multiple myeloma.

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible Multiple Myeloma

Evolving Landscapes in Multiple Myeloma

Web Exclusives

This article summarizes results of the phase 3 IMROZ study, including the frailty subgroup analysis.

BENEFIT: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Transplant-Ineligible NDMM

Evolving Landscapes in Multiple Myeloma

Web Exclusives

Results of the BENEFIT study provide evidence that a weekly bortezomib regimen in isatuximab plus bortezomib, lenalidomide, and dexamethasone can be an effective and feasible option for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

CEPHEUS: Daratumumab + Bortezomib/Lenalidomide/Dexamethasone for Transplant-Ineligible or -Deferred NDMM

Evolving Landscapes in Multiple Myeloma

Web Exclusives

The results of CEPHEUS support the use of daratumumab-based quadruplet therapy for transplant-ineligible or -deferred newly diagnosed multiple myeloma (NDMM).

Respect in the Oncology Navigation Setting

By Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

The Editor’s Take

November 2024 Vol 15, No 11

The term “lay navigator” is derogatory toward the patient navigators who have training in an oncology health–related field and who are recognized by the Centers for Medicare & Medicaid Services as professionals entitled to reimbursement for their specialized services.

Development and Implementation of the Zone Tool for Oncology: A Simple Patient Teaching Tool

By Deanna Schlifke, BSN, RN, OCN; Lin Michelle Tabar, MSN, RN, OCN, CMSRN; Mary Baker, DNP, RN, FNP-C, AOCNP, CHFN, GS-C; Sarah Sumner, PhD, RN, OCN, CCRN, CHPN

Original Research

November 2024 Vol 15, No 11

Researchers share findings from a study on the creation and early use of the Zone Tool for Oncology, a geriatric-friendly, single-page, color-coded symptom self-assessment tool for patients undergoing anticancer treatment.

Clinical Trial Catalyst: Empowering Patients to Talk About Clinical Trials

By Kendra Paabo, BSN, RN; Jennifer West, BSN, RN, CCRC, ONN-CG

Clinical Trial Catalyst, Clinical Trials

November 2024 Vol 15, No 11

In this fourth installment of a 5-part series, the authors provide tools for navigators to effectively guide patients through the clinical trial experience, with a focus on molecular profiling and genetic testing.

Post-CRT Durvalumab: A Game-Changer for SCLC

Lung Cancer

November 2024 Vol 15, No 11

Durvalumab consolidation therapy improved overall and progression-free survival in patients with limited-stage small cell lung cancer that did not progress after standard-of-care concurrent chemoradiotherapy.

International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer

Highlights From IASLC

November 2024 Vol 15, No 11

Explore curated coverage of select research presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

All Articles

Page 16 of 283

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.